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a b s t r a c t
Aims: To asses differences in treatment effects of a fixed combination of perindopril–
indapamide on major clinical outcomes in patients with type 2 diabetes across subgroups
of cardiovascular risk.
Methods: 11,140 participants with type 2 diabetes, from the ADVANCE trial, were random-
ized to perindopril–indapamide or matching placebo. The Framingham equation was used
to calculate 5-year CVD risk and to divide participants into two risk groups, moderate–high
risk (<25% and no history of macrovascular disease), very high risk (>25% and/or history of
macrovascular disease). Endpoints were macrovascular and microvascular events.
Results: The mean age of participants was 66 years (42.5% female). 1000 macrovascular and
916 microvascular events were recorded over follow-up of 4.3 years. Relative treatment
effects were similar across risk groups, (all P-values for heterogeneity 0.38). Hazard ratios
for combined macro- and microvascular events were 0.89 (0.77–1.03) for the moderate-high
risk and 0.92 (0.81–1.03) for the very high risk. Absolute treatment effects tended to be
greater in the high risk groups although differences were not statistically significant
(P > 0.05).
Conclusions: Relative effects of blood pressure lowering with perindopril–indapamide on
cardiovascular outcomes were similar across risk groups whilst absolute effects trended to
be greater in the high risk group.
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People with type 2 diabetes are considered to be at high risk for
developing cardiovascular disease (CVD) [1]. Nevertheless, there
is a gradation of CVD risk among people with type 2 diabetes as
many factors contribute to this risk. Previous studies examining
the effect of blood pressure lowering have focussed on
treatment effects according to single risk factors [2–5]. Recently,
there has been a shift from focussing on individual risk factors to
absolute cardiovascular risk based on a combination of risk
factors [6]. Moreover, contemporary cardiovascular, diabetes
and hypertension management guidelines recommend inte-
grating several risk factors into total cardiovascular risk
assessment by using prediction models [7–9].
Several CVD prediction models have been developed over
the past decade [10]; the most widely known and used models
are Framingham and SCORE for primary prevention in the
general population and the UKPDS risk engine for the
population with diabetes [11–13]. The publicly available
UKPDS risk engine only calculates the separate risk for either
coronary heart disease or cerebrovascular disease [14,15].
While the Framingham risk equations are derived from
general populations, free of prevalent disease, they do take
diabetes into account and they calculate the risks for overall
cardiovascular disease, including coronary heart disease and
cerebrovascular disease [11,12]. As guidelines are increasingly
recommending treatment according to absolute risk, it is
important to define the absolute risks as well as the absolute
effects of various interventions across cardiovascular risk
groups, including those of blood pressure lowering in people
with type 2 diabetes.
The recent Action in Diabetes and Vascular disease:
Preterax and Diamicron Modified Release Controlled Evalua-
tion (ADVANCE) study investigated the effects of routine
administration of a fixed combination of perindopril and
indapamide on macrovascular and microvascular outcomes in
participants with type 2 diabetes [16]. The aim of the present
study was to assess differences in absolute and relative
treatment effects of blood pressure lowering across subgroups
defined by initial absolute cardiovascular risk.
2. Subjects, material and methods
2.1. Study design and participants
ADVANCE was a factorial randomized controlled trial evalu-
ating the effects of routine blood pressure lowering and
intensive blood glucose control on vascular outcomes and
death in participants with type 2 diabetes. Detailed descrip-
tions of the design have been published previously [16,17]. In
brief, 11,140 participants with type 2 diabetes, aged 55 years or
older, with a history of major macrovascular or microvascular
disease, or at least one other risk factor for vascular disease,
were recruited from 215 centres in 20 countries. Patients were
excluded if they had a definite indication for, or contra-
indication to, any of the study treatments, a definite indication
for long-term insulin treatment or were participating in any
other clinical trial.Approval for the trial was obtained from the institutional
ethics committee of each centre and all participants signed an
informed consent.
All potentially eligible participants entered a 6-week active
run-in period during which they received a fixed combination
of perindopril–indapamide (2 mg/0.625 mg). Participants who
tolerated and were compliant with the run-in treatment were
subsequently randomized to continued treatment with
perindopril–indapamide (2 mg/0.625 mg) or matching placebo
and to an intensive blood glucose control strategy aiming for a
HbA1c  6.5% or a standard glucose therapy. The perindopril–
indapamide dose was doubled to 4 mg/1.25 mg after three
months. The use of concomitant treatments during follow-up,
including blood pressure lowering therapy, remained at the
discretion of the responsible physician with two exceptions,
the use of thiazide diuretics was not allowed and open-label
perindopril was the only ACE inhibitor allowed. Participants
were seen at 2 pre-randomization visits, at 3, 4 and 6 months
after randomization and subsequently every 6 months. The
mean follow-up time was 4.3 years for the blood pressure arm
of the study.
2.2. Outcomes
The primary outcomes were composites of major macro-
vascular events (cardiovascular death, nonfatal myocardial
infarction and nonfatal stroke) and microvascular events (new
or worsening nephropathy or retinopathy). The secondary
outcomes included all-cause mortality, cardiovascular death,
all coronary events (death due to coronary heart disease,
including sudden death, nonfatal myocardial infarction, silent
myocardial infarction, coronary revascularisation or hospital
admission for unstable angina), all cerebrovascular events
(death from cerebrovascular events, nonfatal stroke, transient
ischemic attack or subarachnoid haemorrhage) and new or
worsening nephropathy. An independent adjudication com-
mittee reviewed and validated all suspected primary end-
points and deaths.
2.3. Cardiovascular risk assessment
5-year cardiovascular disease risk was estimated using the
Framingham Anderson equation for CVD [12], which is based
on age, gender, smoking status, systolic blood pressure, the
ratio of total/HDL cholesterol, left ventricular hypertrophy and
diabetes status.
CVD risk at baseline was calculated for all participants
using the risk equation. For the 35 participants with missing
values for one of the characteristics included in the equation,
values were imputed using mean substitution. The median
calculated 5-year CVD risk was 18.8% with an interquartile
range of 13.6%–23.5%.
Participants were divided into two risk groups: moderate-
high risk (a calculated CVD risk of 25% over 5 years) and very
high risk (a calculated CVD risk of >25% over 5 years). Only
7.1% (n = 789) of the patients had a calculated risk <10% and
10.8% (n = 85) of these participants had a major macrovascular
or microvascular event. Combining this with the fact that
guidelines classify all patients with type 2 diabetes to be at
least at medium risk for a cardiovascular event [8,18], we did
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ham risk equations do not take account of previous cardio-
vascular event, therefore patients with a history of
cardiovascular disease (n = 3590) were all assigned to the very
high risk group.
2.4. Statistical analysis
Follow-up time for each participant was calculated as time
from registration date to date of event or date of censoring.
The first event for each outcome was included in the analysis.
Mean systolic and diastolic blood pressure were plotted split
out by cardiovascular risk group and treatment arm. Change in
blood pressure was calculated as blood pressure at registration
minus blood pressure at the end of follow-up. The difference
in blood pressure change between the moderate-high and very
high risk groups was tested, stratified for treatment arm, using
a mixed model. Hazard ratios and 95% confidence intervals for
randomized treatment effects on study endpoints were
estimated using unadjusted Cox proportional hazard models.
Homogeneity of treatment effects between the risk subgroups
was tested by adding interaction terms to the relevant Cox
models.
Absolute risk reductions per 1000 persons and for both
subgroups were calculated by subtracting the event rate of the
perindopril–indapamide group from the event rate of the
placebo group. Standard errors from the absolute risk
reductions were obtained and used to calculate 95% confi-
dence intervals following a normal distribution. Differences in
absolute risk reduction between the moderate–high and veryTable 1 – Baseline characteristics of the ADVANCE study popul
and treatment allocation.
Baseline characteristics Moderat
Perindopril–ind
(n = 277
Age (years), mean (sd) 64.8 (5.9
Female, n (%) 1451 (52.3)
Age first diagnosis diabetes (years), mean (sd) 56.8 (8.4
Diabetes duration (years), mean (sd) 8.04 (6.
Previous vascular diseases
History of major macrovascular disease, n (%) n/a 
History of myocardial infarction, n (%) n/a 
History of stroke, n (%) n/a 
History of major microvascular disease, n (%) 276 (10.0)
Blood pressure control
Systolic blood pressure (mmHg), mean (sd) 139 (18.0)
Diastolic blood pressure (mmHg), mean (sd) 79.1 (10.
History of currently treated hypertension, n (%) 1709 (61.6)
Other major risk factors
Current smoking, n (%) 296 (10.7)
Left ventricular hypertrophy, n (%) 45 (1.6) 
Serum haemoglobin A1c concentration (%), media (IQR) 7.2 (6.4
Serum total cholesterol (mmol/l), mean (sd) 5.22 (1.
Serum HDL cholesterol (mmol/l), mean (sd) 1.33 (0.
Urinary albumin-creatinine ratio (mg/mg), median (IQR) 13.8 (7–3
Body mass index (kg2/m), mean (sd) 28.2 (5.5
* Indicates whether baseline characteristic is significantly different (P < high risk groups were tested using a Wald test assuming a
poisson distribution.
Three sensitivity analyses were conducted: (1) using only
those participants without a known history of cardiovascular
disease at baseline; (2) by ranking participants according to their
baseline 5-year coronary heart disease (CHD) risk estimated
with the UKPDS coronary risk engine and dividing all
participants into two groups: moderate–high risk, a predicted
CHD risk of 15% in 5 years and no history of macrovascular
disease, and very high risk, a predicted CHD risk of >15% in 5
years and/or a history of macrovascular disease); (3) by
calculating 10-year CVD mortality risk using systematic
coronary risk evaluation model (SCORE) (13) and dividing all
participants into two groups: moderate–high (a calculated CVD
mortality risk of 15% over 10 years) and very high risk (a
calculated CVD mortality risk of >15% over 10 years).
P-values < 0.05 from two-tailed analysis were considered
statistically significant. All analyses were performed using
SAS Version 9.1.
3. Results
Table 1 shows the baseline characteristics according to CVD
risk group and treatment allocation. Baseline characteristics
of participants were similar for perindopril–indapamide and
placebo within each risk group. Only a difference in the
number of participants who smoked was observed between
the treatment arms in the very high risk group. Table 2a and b
shows the medications at registration and at the end ofation according to 5-year cardiovascular disease risk group
e–high CVD risk Very high CVD risk
apamide
5)
Placebo
(n = 2821)
Perindopril–indapamide
(n = 2794)
Placebo
(n = 2750)
2) 64.7 (6.00) 66.8 (6.58) 66.8 (6.73)
 1474 (52.3) 915 (32.8) 893 (32.5)
8) 56.8 (8.64) 58.9 (8.78) 58.9 (8.71)
31) 7.91 (6.17) 7.92 (6.50) 7.88 (6.4)
n/a 1798 (64.4) 1792 (65.2)
n/a 678 (24.3) 656 (23.9)
n/a 503 (18.0) 520 (18.9)
 286 (10.1) 294 (10.5) 299 (10.9)
 139 (17.6) 151 (23.7) 151 (23.0)
2) 78.9 (10.2) 82.3 (11.6) 82.2 (11.2)
 1748 (62.0) 2093 (74.9) 2105 (76.6)
 318 (11.3) 508 (18.2)* 560 (20.4)*
55 (2.0) 356 (12.8) 362 (13.2)
–8.2) 7.2 (6.5–8.2) 7.2 (6.5–8.2) 7.2 (6.5–8.3)
13) 5.16 (1.12) 5.21 (1.23) 5.21 (1.28)
37) 1.32 (0.37) 1.18 (0.31) 1.19 (0.32)
5) 13.3 (7–32) 16.0 (7–46) 17.6 (8–49)
2) 28.2 (5.39) 28.5 (4.89) 28.5 (4.89)
0.05) between perindopril–indapamide and placebo arm.
Table 2a – Treatment therapies of the ADVANCE study population according to registration and at the end of follow-up for
the moderate high CVD risk group.
Registration visit End of follow-up
Perindopril–indapamide Placebo Perindopril–indapamide Placebo
Blood pressure lowering drugs
Perindopril, n (%) 183 (7) 170 (6) 993 (40) 1264 (51)
Other ACE-I n (%) 789 (28) 859 (30) 93 (4) 97 (4)
ARB, n (%) 137 (5) 153 (5) 190 (8) 290 (12)
B-blockers, n (%) 460 (16) 460 (17) 594 (24) 709 (28)
Calcium antagonists, n (%) 714 (26) 763 (27) 669 (27) 926 (37)
Thiazides, n (%) 385 (14) 388 (14) 68 (3) 101 (4)
Other diuretics, n (%) 221 (8) 218 (8) 273 (11) 307 (12)
Other BP lowering drugs, n (%) 327 (12) 337 (12) 204 (8) 310 (12)
Other drugs
Aspirin, n (%0 901 (32) 881 (31) 1220 (49) 1192 (48)
Other antiplatelets, n (%) 59 (2) 70 (2) 86 (3) 87 (3)
Statins, n (%) 600 (22) 652 (23) 975 (40) 990 (40)
Other lipid modifying drugs, n (%) 244 (9) 238 (8) 194 (8) 161 (6)
Glicazide MR, n (%) 169 (6) 177 (6) 1160 (47) 1151 (46)
Other sulphonylurea, n (%) 1771 (64) 1797 (64) 723 (29) 776 (31)
Metformin, n (%) 1770 (64) 1768 (63) 1727 (70) 1828 (74)
Insulin, n (%) 49 (2) 38 (1) 844 (34) 774 (31)
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groups (Table 2b). Compared to the moderate–high risk group,
the very high risk group received more calcium antagonists,
aspirin and statins at the end of follow-up. Similar proportions of
patients in each risk group received the other medications.
Fig. 1 represents mean systolic and diastolic blood pressure
during follow-up by risk group and treatment arm. The mean
systolic and diastolic blood pressure during follow-up were
higher in the very high risk group compared with the
moderate–high risk group. In both arms of the study a
significant difference in systolic blood pressure between the
risk groups was observed (138 mmHg vs 143 mmHg for the
placebo arm and 132 mmHg vs 138 mmHg for the perindopril–
indapamide arm for the moderate–high and very high riskTable 2b – Treatment therapies of the ADVANCE study populat
the very high CVD risk group.
Registration 
Perindopril–indapamide
Blood pressure lowering drugs
Perindopril, n (%) 307 (11) 
Other ACE-I n (%) 1125 (40) 
ARB, n (%) 152 (5) 
B-blockers, n (%) 884 (32) 
Calcium antagonists, n (%) 955 (34) 
Thiazides, n (%) 400 (14) 
Other diuretics, n (%) 375 (13) 
Other BP lowering drugs, n (%) 373 (14) 
Other drugs
Aspirin, n (%) 1544 (55) 
Other antiplatelets, n (%) 178 (6) 
Statins, n (%) 938 (34) 
Other lipid modifying drugs, n (%) 228 (8) 
Glicazide MR, n (%) 264 (9) 
Other sulphonylurea, n (%) 1800 (64) 
Metformin, n (%) 1630 (58) 
Insulin, n (%) 31 (1) groups respectively, both P-values < 0.001). The mean changes
in systolic blood pressure for the placebo and perindopril–
indapamide treatment arms were 3.70 mmHg (95% CI: 4.47
to 2.93) and 4.42 mmHg (95% CI: 5.19 to 3.65) for the
moderate–high risk group and 11.99 mmHg (95% CI: 12.95 to
11.04) and 11.29 mmHg (95% CI: 12.25 to 10.33) for the
very high risk group respectively. The differences in diastolic
blood pressure change during follow-up between the risk
groups were also significant (P-value < 0.001).
The event rate per year for macrovascular disease was 1.3%
in the moderate–high CVD risk group and 2.9% in the very high
risk group. For microvascular disease the event rate per year
was 1.8% in the moderate–high risk group and 2.0% in the very
high risk group.ion according to registration and at the end of follow-up for
visit End of follow-up
 Placebo Perindopril–indapamide Placebo
279 (10) 1134 (49) 1325 (60)
1110 (40) 138 (6) 115 (5)
167 (6) 263 (11) 330 (15)
925 (34) 900 (39) 963 (43)
995 (36) 861 (37) 1118 (50)
419 (15) 88 (4) 112 (5)
359 (13) 401 (17) 445 (20)
346 (13) 259 (11) 327 (15)
1569 (57) 1463 (63) 1383 (62)
199 (7) 206 (9) 183 (8)
956 (35) 1152 (50) 1141 (51)
226 (8) 198 (9) 147 (7)
255 (9) 1049 (45) 1023 (46)
1723 (63) 741 (32) 705 (32)
1584 (58) 1595 (69) 1554 (70)
41 (1) 737 (32) 657 (30)
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Fig. 1 – Mean blood pressure split out by treatment arm and
CVD risk. Systolic and diastolic blood pressure split out by
5-year CVD risk. Grey solid lines represent the
perindopril–indapamide group, while the black dashed
lines represent the placebo arm.
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arm compared with the placebo arm were similar across both
risk groups for all endpoints including all-cause and cardio-
vascular mortality (Fig. 2, all P-values for interaction 0.38).
Hazard ratios for combined macrovascular and microvascular
events were 0.89 (95% confidence interval: 0.77–1.03) for the
moderate–high risk group and 0.92 (0.81–1.03) for the very high
risk group. Similar results were found when participants with
a history of macrovascular disease at baseline were excluded
(online supplementary Fig. 1).
The absolute risk reductions for macrovascular events
were greater in the very high risk group (11.7% (95% CI: 5.7 to
29.1)) compared to the moderate–high risk group (3.7% (95% CI:
8.2 to 15.7)), but did not achieve statistical significance (all P-
values for difference >0.05) (Table 3). In contrast for
microvascular events the absolute risk reduction in the
perindopril–indapamide group tended to be greater in the
high risk group (9.4) compared to the very high risk group (4.3)
(P for difference >0.05).
When patients with a history of macrovascular disease
at baseline were excluded the absolute risk reductions
were greater in the very high risk group compared to themoderate–high risk group for all endpoints except for
nephropathy (online supplementaryTable 1). Sensitivity
analyses using the UKPDS risk engine produced similar
results for both relative and absolute risk reductions (data not
shown). Similar results were also obtained using the SCORE
model to estimate the relative and absolute treatment effects
for CVD mortality risk groups, as shown in the online
Supplementary Table 2 and Fig. 2.
4. Discussion
In this study of 11.140 participants with type 2 diabetes from
the ADVANCE trial, relative treatment effects of routine blood
pressure lowering with the fixed combination of perindopril
and indapamide on CVD were consistent across subgroups
defined by initial cardiovascular risk score. We also observed a
trend toward greater absolute risk reductions in participants
with very high initial cardiovascular risk compared to
participants with moderate–high risk, though this was not
significant. In contrast the reverse trend was observed for
microvascular events, where the absolute treatment effects
were non-significantly greater in the lower risk group.
Previous studies focussing on the ADVANCE trial have
shown a consistency in relative treatment effect across risk
groups defined by individual risk factors, such as albuminuria
[19], age [20] and cognition [21]. We have now shown that the
treatment effects of blood pressure lowering are consistent
across CVD risk groups defined by a combination of risk
factors, that is, by the total absolute cardiovascular risk.
Recently, there has been a shift from focussing on single
risk factors to multiple risk factors for determining appropri-
ate treatment strategies in routine clinical practice [22].
Observational studies have shown that several risk factors
contribute to the cardiovascular disease risk [23]. People who
are at low risk based on a single risk factor may be at high risk
for developing cardiovascular disease when risk is calculated
on the basis of multiple risk factors [22]. The absolute
difference in risk may vary more than 20-fold in patients
who have the same blood pressure and the same cholesterol
levels [24–26]. Therefore guidelines now recommend multi-
variable risk models to determine treatment strategies.
However, the effects of such approaches have not been
investigated in patients with type 2 diabetes. Our results show
that although the relative risk reductions are very similar
across CVD risk groups, the absolute risk reductions for the
high risk group appear to be greater for macrovascular events
and smaller for microvascular events. However the trend for
microvascular events was reversed, which might be explained
by competing risk. Since patients who are at a very high risk
for developing cardiovascular disease might live longer and
are therefore susceptible for microvascular disease. Another
explanation is that the Framingham risk score, which was
designed to predict major cardiovascular events, is not
suitable for predicting microvascular events. The latter may
also explain the lower magnitude absolute risk reduction
observed for microvascular events within risk groups as
opposed to macrovascular events. It is also important to note
that the ADVANCE blood pressure intervention as previously
reported [16], had no separately significant effect on eye
Fig. 2 – Relative effects of blood pressure lowering across risk groups. Effects of randomized treatment on vascular disease
and mortality events in subgroups according to 5-year predicted CVD risk. Solid boxes represent point estimates with the
area proportional to number of events for the subgroups. The horizontal line represents the 95% CI. The diamonds are the
overall effects for all endpoints.
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outcome in the trial.
Other studies have found comparable results. In a much
smaller population with diabetes, the microHOPE study
showed that relative risk reductions achieved by blood
pressure lowering, were similar across higher risk subgroups
(with a history of macrovascular disease and/or micro-
albuminuria) and lower risk subgroups (without a history of
macrovascular disease and/or micro-albuminuria) [25]. The
systolic hypertension in the elderly program (SHEP) study
included elderly participants with normal glucose tolerance,
but with systolic hypertension, and calculated their CVD risk
using the global risk score, which is based on Framingham.
They observed much higher CVD event rates in high risk
groups, and the number-needed-to-treat (NNT) to prevent one
cardiovascular event decreased progressively at higher pre-
dicted CVD risk [27]. A simulation study focussing on patients
with diabetes found similar results [28]. Combining these
results with our study suggests that similar relative benefits
may be achieved by treating patients similarly regardless of
their initial CVD risk, but absolute benefits will be greater in
patients at highest risk.The strengths of our study include the large sample size
and the recruitment of participants from around the world.
Another strength is the similarity of the results obtained with
sensitivity analyses using a number of different risk equations
such as the UKPDS and SCORE equations. Some limitations
need to be highlighted. First, the ability of the Framingham
equation to accurately predict CVD in participants with type 2
diabetes enrolled in the ADVANCE study was only moderate as
previously reported [29]. However, as the Framingham
equation is the most widely used prediction model in clinical
practice, it was felt to be the most suitable model for use in this
study. Second, the power of this study to detect small changes
in relative risk across the broader risk groups was limited due
to the study necessarily including patients with type 2
diabetes who are considered at increased risk for cardiovas-
cular events. Third, the differences in absolute risk reduction
between the two risk groups were not significant, reflecting at
least in part limitations in statistical power due to the small
number of events occurring in each group. Lastly the
systematic coronary risk evaluation model (13), derived from
a broader population without accounting for diabetes status
may be less suitable for application in people with diabetes.
Table 3 – Absolute risk reduction by subgroups of CVD risk.
CVD risk groups Cumulative incidence rate for study
period
Absolute risk reduction
n per 1000 persons (95% CI)
P-value for
difference in ARR
Perindopril–indapamide Placebo
Combined macro + micro 0.962
Moderate–high 0.120 0.134 14.0 (3.4 to 31.4)
Very high 0.189 0.204 14.7 (6.3 to 35.6)
Macrovascular event 0.459
Moderate–high 0.053 0.057 3.7 (8.2 to 15.7)
Very high 0.119 0.131 11.7 (5.7 to 29.1)
Microvascular event 0.619
Moderate–high 0.073 0.082 9.4 (4.6 to 23.5)
Very high 0.085 0.089 4.3 (10.6 to 19.1)
All deaths 0.822
Moderate–high 0.045 0.056 10.6 (0.8 to 22.1)
Very high 0.101 0.114 12.9 (3.4 to 29.2)
Cardiovascular death 0.508
Moderate–high 0.020 0.026 6.1 (1.8 to 13.9)
Very high 0.056 0.067 11.1 (1.5 to 23.7)
Total coronary events 0.189
Moderate–high 0.048 0.053 5.6 (5.9 to 17.1)
Very high 0.120 0.140 19.7 (2.0–37.5)
Total cerebrovascular events 0.503
Moderate–high 0.039 0.039 0.4 (9.7 to 10.6)
Very high 0.064 0.070 6.1 (7.1 to 19.3)
Nephropathy 0.213
Moderate–high 0.027 0.029 2.0 (6.6 to 10.6)
Very high 0.038 0.049 10.8 (0.0–21.6)
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macrovascular and microvascular outcomes were similar
across cardiovascular risk groups among participants with
type 2 diabetes. However, absolute risk reductions for
macrovascular outcomes tended to be greater in the very
high risk group compared to the moderate–high risk group,
indicating that greater absolute benefits might be achieved in
patients with diabetes at highest risk. It is therefore important
to identify these patients and treat them intensively in order to
improve their outcomes.
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